MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:MAJI)

0.0748 UNCHANGED
Streaming Delayed Price Updated: 11:04 AM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0748
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0748
Today's Range 0.0748 - 0.0748
52wk Range 0.0250 - 0.3199
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exousia Pro Announces Breakthrough In Exosome-Based Delivery
Via ACCESS Newswire
Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
Via ACCESS Newswire

Performance

YTD
+36.0%
+36.0%
1 Month
-50.0%
-50.0%
3 Month
-31.9%
-31.9%
6 Month
-62.6%
-62.6%
1 Year
+91.8%
+91.8%

More News

Read More
Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes
Via ACCESS Newswire
Exousia Pro Reports Positive Outcome in Legal Proceeding
Via ACCESS Newswire
Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets
Via ACCESS Newswire
Exousia Pro Creates New Subdivisions
Via ACCESS Newswire
Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division
Via ACCESS Newswire
Exousia Pro Files Reg A.
Via ACCESS Newswire
Exousia Pro Expands its Scientific Advisory Board
Via ACCESS Newswire
Exousia Pro Will Launch a Web Series with Our New Consultant
Via ACCESS Newswire
Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application
Via ACCESS Newswire
Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview
Via ACCESS Newswire
Exousia Pro Offers Guidance on New Subdivisions
Via ACCESS Newswire
Exousia Pro to Deliver 500 Billion Dried Exosomes for Trade Show
Via ACCESS Newswire
Exousia Pro Issues Update on Name Change
Via ACCESS Newswire
Exousia Pro Has Appointed Matthew Dwyer As Its New President
Via ACCESS Newswire
Exousia Pro Issues and Update on its FDA Orphan Drug Status
Via ACCESS Newswire
Exousia Pro Officially Announces the Production of Plant-Based Exosomes Has Begun
Via ACCESS Newswire
Exousia Has Successfully Renegotiated Its License Agreement
Via ACCESS Newswire

Frequently Asked Questions

Is MAJI publicly traded?
Yes, MAJI is publicly traded.
What exchange does MAJI trade on?
MAJI trades on the OTC Traded
What is the ticker symbol for MAJI?
The ticker symbol for MAJI is MAJI on the OTC Traded
What is the current price of MAJI?
The current price of MAJI is 0.0748
When was MAJI last traded?
The last trade of MAJI was at 11/07/25 11:04 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story